Arthritis, Osteoarthritis pain, Joint disease

Ampio Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company primarily engaged in the development of AmpionTM, its lead anti-inflammatory drug, which is currently undergoing clinical trials focused on the treatment of patients afflicted with COVID-19 induced acute respiratory distress syndrome (ARDS) as well as patients suffering from severe (KL-4) osteoarthritis of the knee (OAK).  Both conditions impact a significant percentage of the population and due to the lack of any FDA approved drugs for treatment, there exists a significant unmet medical need.  Ampion is backed by an extensive global patent portfolio with intellectual property protection extending through 2035.  In addition, Ampion will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the biologics price competition and innovation act (BPCIA).

Drug & Indication	Stage & Event	Catalyst Date
Ampion (Osteoarthritis) Details Arthritis, Osteoarthritis pain, Joint disease	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ampion Details COVID-19	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.

Drug Pipeline

Powered by